This information is disclosed in accordance with the Securities Markets Act, the Financial Instruments Trading Act or demands made in the exchange rules.
Profit before tax SEK 935m (2,047)
Earnings per share before dilution SEK 2.21 (4.93)
Mixed development in the holdings - half with positive trend, half less favourable development
Add-on acquisition of Sophion Bioscience
Medisize sold - exit gain SEK 38m
Total return on Ratos shares -33%
All information related to the interim report can be found here..
Stockholm 9 November 2011
Ratos AB (publ)
For further information:
Arne Karlsson, CEO, +46 8 700 17 00
Emma Rheborg, Head of Corporate Communications & IR, +46 8 700 17 20